Abstract
Objective: to analyze the participation of market representatives in the legitimate gateway to the process of incorporating technologies into SUS. Method: this is a descriptive, retrospective study, based on secondary data on demands for health technology assessment received by CONITEC. Theoretical basis: there are indications in the literature that the pharmaceutical industry uses the judicialization of health in Brazil, as a shortcut for the introduction of new drugs in SUS. Results: market representatives are the second largest demand for health technology assessment by CONITEC. Less than 40% of their requests are converted into opinions favorable to the incorporation into SUS. Most requests originating from the judiciary have also not resulted in a favorable opinion on the incorporation of technology. Conclusion: it is important that opinions issued by CONITEC reach the judiciary to allow the sentences handed down in Brazilian courts to have technical and scientific support, in order to prevent the pharmaceutical industry from using shortcuts to introduce technologies in the public health system.